TG Therapeutics, Inc. (TGTX)
TG Therapeutics: 'Strong Buy' Amid BRIUMVI Expansion Win And Boosted 2026 Outlook
TG Therapeutics remains a "Strong Buy" as BRIUMVI drives robust revenue growth and pipeline expansions. The company raised 2026 BRIUMVI sales guidance to $885–$900 million, reflecting 63% year-over-year Q1 sales growth and strong market momentum. Phase 3 ENHANCE trial success with single 600 mg IV BRIUMVI dosing supports label expansion and competitive positioning in the RMS market.
TGTX's Single-Dose Briumvi Hits Bioequivalence Goal in MS Study
TG Therapeutics announces that Briumvi's late-stage ENHANCE study met its goal, supporting a potential single-infusion regimen for relapsing MS patients.
TGTX Stock Rises 29% in 3 Months: Here's What You Should Know
TG Therapeutics gains on strong Briumvi sales growth, higher 2026 revenue guidance and advancing late-stage studies in RMS.
Historic Signal Says This Biotech Outperforms
TG Therapeutics Inc (NASDAQ:TGTX) is trading down 1.2% at $42.35, after last week being rejected by the overhead $44 ceiling.
TGTX Q1 Earnings Miss, Sales Rise Y/Y, Stock Up on Raised 2026 View
TG Therapeutics misses Q1 earnings estimates, but strong Briumvi sales drive y/y revenues. Shares rise as the company raises 2026 revenue outlook.
TG Therapeutics, Inc. (TGTX) Q1 2026 Earnings Call Transcript
TG Therapeutics, Inc. (TGTX) Q1 2026 Earnings Call Transcript
TG Therapeutics (TGTX) Q1 Earnings Lag Estimates
TG Therapeutics (TGTX) came out with quarterly earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.23 per share. This compares to earnings of $0.03 per share a year ago.
TG Therapeutics (TGTX) to Report Q1 Results: Wall Street Expects Earnings Growth
TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TG Therapeutics: Flawless Execution And $500 Million Non-Dilutive Capital Bolster Outlook
TG Therapeutics is downgraded from Strong Buy to Buy after a 17% rally, reflecting a now fairer valuation. Briumvi IV continues to gain market share in MS, while the SC version's trial is fully enrolled and could double the addressable market. Management guides conservatively for 2026 Briumvi U.S. net revenue of $825–$850 million and maintains disciplined operating expense targets.
TGTX Completes Enrollment in Phase III Study on Subcutaneous Briumvi
TG Therapeutics completes enrollment in a phase III study of subcutaneous Briumvi for treating RMS in adults, with data expected by late 2026 or early 2027.
TG Therapeutics: Briumvi Performance Aiding Upside, Buybacks Limiting Downside
Briumvi's US net product revenues reached $182.7M in Q4'25, with 19.5% sequential growth, and 2026 global revenue guidance is $875M–$900M. Key catalysts include the ENHANCE trial readout (mid-2026) and pivotal subcutaneous Briumvi data (year-end 2026/1Q 2027), both with significant upside potential. TGTX's $300M buyback program could provide downside support, although material negative updates are still a risk even with the buyback program in place.
TG Therapeutics: 'Strong Buy' On BRIUMVI's Massive Growth And Possible Expansion
TG Therapeutics remains a "Strong Buy," driven by robust BRIUMVI revenue growth and ambitious expansion initiatives. The company reported $594 million in 2025 U.S. BRIUMVI sales, a 90% YoY increase, and guides for $825–$850 million in 2026. Key catalysts include the phase 3 ENHANCE study (consolidated dosing) and a self-administered subcutaneous BRIUMVI, both targeting significant market segments.
